Heartland Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Heartland Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-70,000	Closed	-$11.6M	–	239
2020 Q4	$11.6M	Sell	70,000 -10,000	-13%	-$1.49M	0.83%	28
2020 Q3	$11.4M	Hold	80,000	–	–	0.99%	17
2020 Q2	$8.83M	Sell	80,000 -20,000	-20%	-$2.21M	0.79%	41
2020 Q1	$9.97M	Buy	100,000 +20,000	+25%	+$2.59M	1.07%	20
2019 Q4	$11.9M	Hold	80,000	–	–	0.88%	31
2019 Q3	$10.3M	Buy	80,000 +10,000	+14%	+$1.34M	0.78%	39
2019 Q2	$9.98M	Hold	70,000	–	–	0.73%	49
2019 Q1	$10M	Buy	+70,000	New	+$9.13M	0.74%	53

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Heartland Advisors's JAZZ Position: Q1 2021 in Review

Heartland Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2021, closing a stake of 70,000 shares — an estimated $11.6M sold.

Heartland Advisors first reported a position in JAZZ in Q1 2019 and held it in 8 quarters. The position peaked at $11.9M in Q4 2019. 441 funds tracked by Wall St. Rank hold JAZZ as of Q1 2021.

Heartland Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Heartland Advisors sold 70,000 Jazz Pharmaceuticals shares in Q1 2021, an estimated $11.6M.
Heartland Advisors first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 8 quarters.
Heartland Advisors's Jazz Pharmaceuticals position peaked at $11.9M in Q4 2019.
441 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2021.

Based on Heartland Advisors's 13F filing for Q1 2021, filed 12 May 2021.